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Background: Activation of platelets and endothelial cells plays an important role in the
pathogenesis of atherosclerosis and thrombotic disorders.
The aim of our study was to assess the relationship between themetabolic disorders and
markers of platelet activity and vascular injury in patient with acute ischemic stroke.
Material and methods: The study group consisted of 84 patients with acute non-lacunar
ischemic stroke divided into four subgroups with: (1) normolipidemia and normoglycemia,
(2) normolipidemia and hyperglycemia, (3) hyperlipidemia and normoglycemia, (4) hyper-
lipidemia and hyperglycemia. 21 healthy subjects served as controls. We analyzed the
concentration of adhesion molecules sP-selectin and sE-selectin in serum collected from
all studied groups using ELISA method.
Results: We observed signiﬁcantly higher sE- and sP-selectin concentration in patients with
hyperglycemia and hyperlipidemia compared to both control subjects and patients with
normolipidemia and normoglycemia. We did not observe additional effect of comorbid
hyperlipidemia and hyperglycemia on studied markers. Soluble E- and P-selectin concen-
tration correlated positively with LDL, TC and HbA1c level in all stroke patients.
Conclusion: Soluble E- and P-selectin, blood markers of vascular injury and platelet activa-
tion, could be useful in the assessment of atherothrombotic properties of hyperglycemia and
hyperlipidemia in stroke patients.
© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.1. IntroductionIschemic stroke is thought to be the consequence of
atherosclerosis, plaque inﬂammation and rupture, thrombosis* [109_TD$DIFF]Corresponding author.
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0028-3843/© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Nand brain infarction. The key role in the pathogenesis of
atherothrombosis play changes in the vascular endothelium
and platelets activation [1].
E-selectin and P-selectin are glycoproteins belonging to the
selectin family of adhesionmolecules. They regulate adhesivek).
eurological Society.
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thelium and are believed to play an important role in
atherogenesis and plaque inﬂammation [2]. P-selectin is a
membrane molecule of the a-granules in platelets and of the
endothelial Weibel-Palade bodies. E-selectin is expressed on
activated vascular endothelium only. Soluble form of P- and E-
selectin are released into the serum by a sheddingmechanism
and their rise are observed in plasma of patients with vascular
diseases and reﬂect activation of endothelial cells and
platelets as well [3]. The increased plasma concentration of
soluble P-selectin reﬂects the release of these adhesion
molecule from activated platelets or damaged endothelial
cells whereas high soluble E-selectin reﬂects only vascular
endothelium damage. Elevated concentration of sP-selectin
can exert procoagulant activity [4] and it might play an
important role in thrombotic disorders. Assessment of soluble
P-selectin, originating from platelets and endothelial cells,
may be amarker of increasedmembrane P-selectin expression
connected with vascular dysfunction and platelet activation.
This adhesionmoleculemay provide complete information on
dynamic interactions between endothelial and circulating
cells [5].
Hyperglycemia and dyslipidemia are signiﬁcant and
independent risk factors for the vascular diseases. They are
the key factors in the platelet activation and development of
atherosclerosis. Hyperglycemia plays an important role in the
blood abnormalities leading to a prothrombotic state in
diabetes mellitus (DM) patients [6,7]. The most important
factors are increased coagulation, impaired ﬁbrinolysis,
endothelial dysfunction and platelet hyperreactivity [8,9].
Platelets from patients with DM have increased expression of
adhesion molecules. It was showed that platelets from
these patients have a greater expression of platelet activation
markers (CD31, CD49b, CD62P and CD63) compared with the
age-matched non-diabetic control group, and a signiﬁcant
positive correlation between HbA1c concentration and both
CD62P and CD63 expression have been observed [10].
Platelet dysfunction in diabetic patients is caused by several
mechanisms, such as hyperglycemia, insulin deﬁciency and
associated metabolic conditions like dyslipidemia [11].
Modiﬁcation of lipoprotein in diabetic states, including
peroxidation and glycation, may be one of the mechanisms
responsible for diabetic complications [12,13]. Oxidation may
increase atherogenicity of lipoproteins, whereas glycation
may enhance the oxidative stress of the lipoproteins [14].
Low-density lipoproteins (LDLs) have been reported to
activate platelets and increase platelets reactivity to platelet
agonists [15]. Platelets activated by native and oxidized LDL
(ox-LDL) release factors which increase the number of LDL
receptors on macrophages and stimulate LDL accumulation
in these cells [16]. Thus, ox-LDL may impair vascular
functions, resulting in increased risk of occlusive thrombotic
events [17].
These ﬁndings show that the interaction of hyperglycemia
and dyslipidemia may increase the risk of vascular complica-
tions independently as well as synergistically.
The aim of this study was to access the inﬂuence of
hyperlipidemia and hyperglycemia on soluble P- and E-
selectin concentration in the blood of patients with acute
ischemic stroke.The study was approved by the Ethics Committee of
Medical University of Lodz, Poland (No. RNN/465/11/KB).
2. Material and methodsThe study group consisted of 84 patients admitted to the
Department of Neurology and Stroke Medical University of
Lodz, Poland with a diagnosis of acute ischemic stroke. The
diagnosis was established by history, clinical examination,
and cerebral CT orMRI scans. Patientswith non-lacunar stroke
and metabolic disorders like hyperlipidemia and hyperglyce-
mia were included to the study. The diagnosis of diabetes
mellitus in patients with hyperglycemia was established
before the hospitalization and diabetic patients were included
to the study if HbA1c was higher than 7% in spite of
hypoglycemic treatment (metformin, glimepiride, gliclazide,
insulin therapy). The hyperlipidemia was recognized on the
basis of low-density lipoproteins cholesterol (LDL-C) level ≥
2.6 mmol/l (100 mg/dl).
The stroke patients were divided into four groups:(1) 21 patientswith normolipidemia and normoglycemia –NL/
NG: LDL < 2.6 mmol/l (100 mg/dl) [18], mean 2.20  0.32
mmol/l.; HbA1c ≤ 7% [19], mean 5.7  0.3%; 10 males, 11
females, mean age 75.76  10.9 years;(2) 21 patients with normolipidemia and hyperglycemia – NL/
HG: LDL < 2.6 mmol/l (100 mg/dl), mean 2.33  0.34
mmol/l; HbA1c > 7%, mean 7.67  0.82%; 12 males, 9
females, mean age 73.8  12.6 years;(3) 21 patients with hyperlipidemia and normoglycemia – HL/
NG: LDL ≥ 2.6 mmol/l (100 mg/dl),mean 3.23  1.28 mmol/
l; HbA1c ≤ 7%, mean 5.53  0.33%; 9 males, 12 females,
mean age 71.04  13.05 years;(4) 21 patients with hyperlipidemia and hyperglycemia – HL/
HG: LDL ≥ 2.6 mmol/l (100 mg/dl),mean 3.26  0.56 mmol/
l; HbA1c > 7%, mean 7.91  1.16%; 13 males, 8 females,
mean age 70.1  10.76 years.
All studied stroke patients received 300 mg of ASA
(acetylsalicylic acid) on the ﬁrst day of hospitalization and
they continued the treatment receiving 75 mg of ASA during
the next days. The patients in control group received ASA
75 mg /day.
Control subjects consisted of patients hospitalized in the
Department of Neurology and Stroke (n = 21; 10 males, 11
females, mean age 60.2  14.6 years) with normolipidemia
and normoglycemia without a history of cerebrovascular
diseases.
The exclusion criteria involved a history of infection shortly
before stroke, severe liver disease, renal failure, evidence of
malignant, chronic inﬂammatory diseases and haemorrhagic
diathesis. The risk factors for ischemic stroke (arterial
hypertension, ischemic heart disease and body mass index)
were similar in the study groups and the controls, and patients
in all groups were receiving antihypertensive drugs, such as
ACE inhibitors, calcium channel blockers, b-blocker).
The blood lipid proﬁle and HbA1c level in study groups are
presented in Table 1. Complete blood cell count, HbA1c, total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
Table 1 – The blood lipid profile and HbA1c level (means W SD) in study groups.
Parameters NL/NG NL/HG HL/NG HL/HG CS
TC [mmol/l] 3.61  0.58 3.77  0.46 5.38  0.74 5.86  0.46 4.06  0.5
LDL [mmol/l] 2.20  0.35 2.33  0.34 4.18  1.01 4.28  0.56 2.45  0.13
HDL [mmol/l] 1.08  0.33 1.07  0.31 1.3  0.29 1.14  0.25 0.95  0.17
TG [mmol/l] 1.39  0.77 1.56  0.7 1.81  0.91 1.67  0.61 1.31  0.48
HbA1c [%] 5.71  0.3 7.5  0.9 5.54  0.34 7.66  1.3 5.22  0.37
SD, standard deviation; TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG,
triglyceride; HbA1c, glycosylated hemoglobin A1c.
NL/NG, normolipidemic/normoglycemic group; NL/HG, normolipidemic/hyperglycemic group; HL/NG, hyperlipidemic/normoglycemic group;
HL/HG, hyperlipidemic/hyperglycemic group; CS, control subjects.
[(Fig._1)TD$FIG]
Fig. 1 – Soluble P-selectin concentration in study groups. NL/
NG, normolipidemic/normoglycemic group; NL/HG,
normolipidemic/hyperglycemic group; HL/NG,
hyperlipidemic/normoglycemic group; HL/HG,
hyperlipidemic/hyperglycemic group; CS, control subjects.
[(Fig._2)TD$FIG]
Fig. 2 – Soluble E-selectin concentration in study groups. NL/
NG, normolipidemic/normoglycemic group; NL/HG,
normolipidemic/hyperglycemic group; HL/NG,
hyperlipidemic/normoglycemic group; HL/HG,
hyperlipidemic/hyperglycemic group; CS, control subjects.
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 9 9 – 6 0 5 601low-density lipoproteins cholesterol (LDL-C) levels were done
in fasting state in all patients. Serum LDL-C levels were
calculated with Friedewald's formula. Biochemical determi-
nations were performed with the Olympus AU640 Analyzer
(Olympus Optical Co., Ltd., Shizuoka, Japan). Plasma samples
were taken within 7 days after onset of symptoms. After
10 min of centrifugation, the blood plasma obtained from
EDTA-anticoagulated samples was stored at 80 8C until
measurements. Blood concentration of sP-and sE-selectin
were measured with commercially available ELISA kits (R&D
Systems, Abingdon, UK). Measurementwas performed accord-
ing to the manufacturers' instructions.Table 2 – Medians of soluble P- and E-selectin concentration in
Study parameters
CS NL/NG
sP-selectin [ng/ml] 72.15 100.1
sE-selectin [ng/ml] 28.95 27.42
NL/NG, normolipidemic/normoglycemic group; NL/HG, normolipidemic/h
HL/HG, hyperlipidemic/hyperglycemic group; CS, control subjects.
# p < 0.05 vs NL/NG.
* p < 0.05 vs CS.
## p < 0.01 vs NL/NG.
** p < 0.001 vs CS.3. Statistical methodsSince all study variable did not passed D'Agostino normality
test differences between groups were analyzed with the
Kruskal-Wallis test followed by post-hoc Duna test for
multiple comparisons adjustment. A Spearman's correlation
was run to assess the relationship between continuous
variables. All of the statistical analyses were performed using
Statistica for Windows ver. 8.0. The null hypothesis was
rejected if p < 0.05.blood of the study patients and control subjects.
Median
NL/HG HL/NG HL/HG
128.9**,# 132.7**,## 131.5**,##
48.38* 44.61*,# 51.44**,##
yperglycemic group; HL/NG, hyperlipidemic/normoglycemic group;
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 9 9 – 6 0 56024. ResultsThe data of our research conﬁrm the signiﬁcant inﬂuence of
metabolic disturbances on sP- and sE-selectin serum concen-
tration level in stroke patients. We observed signiﬁcantlyTable 3 – The correlation between soluble P- and E-selectins co
Parameters TC LDL
sP-selectin [ng/ml] p < 0.01
R = 0.288
p < 0.01
R = 0.404
sE-selectin [ng/ml] p < 0.01
R = 0.312
p < 0.01
R = 0.386
TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high
hemoglobin A1c.
[(Fig._3)TD$FIG]
Fig. 3 – Correlation between soluble P- and E-selectin concentra
total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, h
glycosylated hemoglobin A1c.higher sP-selectin concentration in patients with hyperglyce-
mia and hyperlipidemia as compared to control subjects (NL/
HG, HL/NG, HL/HG vs CS, p < 0.001) and group without
comorbid hyperglycemia and hyperlidipemia (NL/HG vs NL/
NG, p < 0.05; HL/NG, HL/HG vs NL/NG, p < 0.01 (Table 2 and
Fig. 1).ncentration, lipid parameters and HbA1c in study patients.
HDL TG HbA1c
p > 0.05
R = 0.08
p > 0.05
R = 0.097
p < 0.01
R = 0.433
p > 0.05
R = 0.127
p < 0.05
R = 0.225
p < 0.01
R = 0.370
-density lipoprotein cholesterol; TG, triglyceride; HbA1c, glycosylated
tion and lipid parameters and HbA1c in study patients. TC,
igh-density lipoprotein cholesterol; TG, triglyceride; HbA1c,
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tion. Higher serum concentration of sE-selectin was noticed in
stroke patients with metabolic disorders compared to control
subjects (NL/HG,HL/NG vs CS, p < 0.05; HL/HG vs CS, p < 0.001)
and compared to stroke patient with normolipidemia and
normoglycemia (HL/NG vs NL/NG, p < 0.05, HL/HG vs NL/NG,
p < 0.01) (Table 2 and Fig. 2).
Positive correlations between serum concentration of sP-
and sE-selectin and total cholesterol, LDL, HbA1c, p < 0.01)
(Table 3 and Fig. 3) were observed.
Against all expectations we did not observe signiﬁcantly
higher concentration of sP- and sE-selectin in group of patient
with comorbid hyperlipidemia and hyperlipidemia compared
to patients with hyperlipidemia or hyperglycemia.
5. DiscussionHyperlipidemia and the hyperglycemia are considered as the
major risk factors for the development of atherosclerosis and
platelet activation.
The principalﬁnding of our study is a signiﬁcant correlation
of hyperlipidemia and hyperglycemia with increased serum
concentration of sP-selectin and sE-selectin in stroke patients.
Our study also showed signiﬁcant positive correlation between
the increased LDL, total cholesterol, HbA1c level and the high
concentration of soluble E-selectin and P-selectin. In spite of
our expectations, we did not observe additional effect of
comorbid hyperlipidemia and hyperglycemia on serum con-
centration of studied markers.
The pathophysiological signiﬁcance of the increased P-
selectin serum level in hypercholesterolemic or hyperglycemic
patients still remains unclear. Making under consideration the
origin of sP-selectin we cannot be sure if high sP-selectin level
observed in our study is the result of platelet activation or
endothelial cells injury. However, in our study soluble E-
selectin as a marker of endothelial activation has also been
found to be elevated in all stroke patients with dyslipidemia
and hyperglycemia. It has been proposed that these soluble
cell adhesion molecules may represent a marker of the
endothelial atherosclerotic damage. These ﬁndings partly
suggest endothelial origin of sP-selectin. Further, it is believed
that metabolic disturbances like hyperlipidemia and hyper-
glycemia are the factors with strong atherogenic properties.
The positive correlation between high lipid proﬁle (LDL and
total cholesterol), high HbA1c level and markers of endothelial
damage: sE- and sP-selectin, conﬁrm this observation. Simi-
larly, Ferroni et al. [20] and Davi et al. [5] demonstrated the
relationship between the increased LDL concentration and the
plasma sP-selectin level. Elevated soluble P-selectin level in
hyperlipidemic patients with type 2 diabetes, and association
with increased oxidised LDL were also demonstrated by
Nomura et al. [21]. In other study E-selectin as a marker of
endothelial dysfunction have also been elevated in dyslipi-
demic patients [22]. Possible reasons for the increase in blood
marker of endothelial dysfunction is activation of the
symptomatic atherosclerotic plaque. Signiﬁcant increase of
vascular injury markers in stroke patients with metabolic
disturbances conﬁrm important inﬂuence of hyperlipidemia
and hyperglycemia on atherosclerosis progression and ath-erosclerotic plaque instability. However, the role of blood
platelets in the development and proliferation of atheroscle-
rotic lesions is also signiﬁcant and largely results from their
interactions with damaged endothelial cells [23].
Circulating atherogenic lipoproteins have been shown to
activate circulating blood platelets, and thereby contribute to
the pathogenesis and progression of atherothrombosis [24,25].
Furthermore, hyperglycemia plays an important role in
platelet dysfunction, including altered adhesion and aggrega-
tion, even in the absence of vascular injury [11]. Thus,
increased sP-selectin concentration observed in our study
may reﬂects not only endothelial dysfunction but also
platelets activation in stroke patients with metabolic dis-
turbances. This observation is concordant with ﬁndings of the
other studies that conﬁrmed the inﬂuence of hyperlipidemia
and high glucose concentration on platelet activity and
enhanced expression of platelet P-selectin [26–28].
The results of our study also conﬁrmed earlier reports of a
signiﬁcant increase of sP-selectin and sE-selectin concentra-
tions in acute ischemic stroke [29–32]. We observed elevated
bloodmarkers of endothelial and platelet activation during the
ﬁrst 7 days after brain ischemia in all groups of stroke patients
even without concomitant hyperlipidemia and hyperglyce-
mia. The early increase of sP-selectin and sE-selectin may be a
result of inﬂammation and activation of the atherosclerotic
plaque, atherothrombosis after plaque eruption, and ischemic
neuronal damage causing expression of factors that promote a
further reactions that involve these markers [29]. Moreover,
elevated concentration of sP-selectin can exert its own
procoagulant activity [4] resulting from induction of tissue
factor expression in circulatingmonocytes [33]. These ﬁndings
suggest that an increase in plasma P-selectin concentration
may induce a hypercoagulability state and this adhesive
molecule may represent a risk factor itself [29]. It was also
established that E-selectin plays an important role in the
pathogenesis of tissue injury after cerebral ischemia and
reperfusion [34]. These observations and our ﬁndings suggest
that the increase of sP- and sE-selectin serum level in acute
stroke patients may be not a consequence of atherosclerosis
complication only in patients with comorbid hyperlipidemia
and hyperglycemia but is also observed in stroke patients
without metabolic disturbances and may be the results of
tissue injury after brain ischemia. It suggests that E-selectin
and P-selectin blockade may be clinically useful in stroke
treatment.
However, the limitation of our study is the pretty large time
from the stroke onset to the collection of blood samples. Some
study suggested that lipid and lipoprotein levels of patients
with TIA or stroke should be assessed within a maximum of
48 h after the acute event [35].
Summingup, results of our study point to the leading role of
hyperglycemia andhyperlipidemia in enhanced concentration
of soluble P-selectin and E-selectin, molecules reﬂecting
vascular injury and platelet hyperreactivity. The increased
concentration of these soluble adhesion molecules in athero-
sclerotic ischemic stroke is a consequence of hyperlipidemia
and hyperglycemia inﬂuence on atherogenesis and platelet
activation but on the other hand may also be secondary to
acute ischemic events and may induce a hypercoagulability
status representing a risk factor itself [29]. Measurements of
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 9 9 – 6 0 5604sP- and sE-selectin concentration might be useful as a
predictive marker for the risk of cerebrovascular events
caused by atherothrombotic complication.
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